Size | Price | Stock | Qty |
---|---|---|---|
5g |
|
||
10g |
|
||
Other Sizes |
|
ln Vitro |
A biochemical reagent called palmitic acid (sodium) can be utilized in life science research as an organic compound or biological material.
|
---|---|
ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Rat liver slices were incubated with (14)C-labeled sodium palmitate for 120 min at 37 °C. Lipid fractions extracted & separated by chromatography. Palmitate was maximally incorporated into phospholipid fractions after 5 min. (14)C-1-Palmitate was injected into rabbit fetuses in utero. Fetal liver, blood, carcass & placenta checked for radioactivity. Highest total early specific activity in plasma, but later liver displayed most extensive incorporation. Phospholipid incorporation more rapid. Metabolism / Metabolites The metabolism of radiolabeled acetone, acetate, or palmitate was studied in pregnant and nonpregnant guinea-pigs. Fasted pregnant guinea-pigs and guinea-pigs that were not pregnant were injected intracardially with carbon-14 C-(14) labeled acetone, sodium-acetate, or sodium-palmitate. Doses ranged from 0.4 to 2.2 milligrams per kilogram. Expired carbon-dioxide was collected and assayed for radioactivity. C-(14) content of lipids, and blood and urine total acetone bodies were measured. ... In the palmitate treated animals, specific carbon-dioxide activities were twice as great in the pregnant guinea-pigs. Liver lipid C-(14) content of the group that were not pregnant was twice that of the pregnant group. The authors conclude that pregnant guinea-pigs used C-(14) more for biosynthesis than for carbon-dioxide excretion, while the opposite is true for guinea-pigs that were not pregnant. Fat cells isolated from rat epididymal adipose tissue were incubated with albumin-bound (14)C-palmitate. Incorporation of (14)C into (14)CO2, and glycerides was measured. Some evidence is presented to suggest that the exogenous palmitate pool is in isotopic equilibrium with intracellular precursors for these metabolic processes. Precautions were taken to minimize dilution of the exogenous palmitate pool by fatty acids released from the cells. (14)CO2 production from (1-(14)C)-palmitate was 3 times that from (16-(14)C)-palmitate. Octanoate increased this differential oxidation of palmitate carbons and also inhibited palmitate oxidation without similarly affecting esterification. Glucose increased palmitate esterification in cells from fed or starved rats. Insulin potentiated this effect of glucose. Glucose influenced palmitate oxidation in a more complex manner, dependent upon the glucose concentration. Both the observation that esterification constitutes 99% of the metabolic flux of fatty acid and the manner in which glucose, insulin, or starvation influence palmitate esterification and oxidation suggested that factors controlling esterification may alter oxidation as a secondary effect, but not vice versa. It is suggested that oxidation and esterification compete for a single intracellular precursor, possibly extramitochondrial long chain fatty acyl COA. /Palmitate/ |
Toxicity/Toxicokinetics |
Interactions
Upper body obesity is associated with insulin resistance, hypertension, and endothelial dysfunction. /The authors/ examined forearm vascular function in response to vasodilator (endothelium-dependent and endothelium-independent) and vasoconstrictor stimuli in 8 normotensive, upper body/viscerally obese men with a positive family history of hypertension and 8 age-matched nonobese men ... Body composition and insulin regulation of free fatty acid (FFA) and glucose metabolism /were also measured/. Forearm blood flow was measured before and during brachial artery infusions of acetylcholine (Ach), sodium nitroprusside (NTP), and angiotensin II (+ / - nitric oxide synthase (NO)) synthase blockade with N(G)-monomethyl L-arginine (L-NMMA). On a separate day, baseline and insulin-regulated glucose ((3-(3)H)glucose) and FFA ((9,10-(3)H)palmitate) turnover were measured. The vasoconstrictor response to angiotensin II was greater (P<0.05) in obese men than in nonobese men, whereas endothelium-dependent vasodilation was similar. The slope of the angiotensin II dose-response curve correlated significantly with the basal plasma palmitate concentration. Basal and insulin-mediated glucose disposal was significantly reduced and FFA turnover significantly increased in viscerally obese men. No differences in endothelium-independent vasodilation or relationships between vascular responsivity and palmitate and glucose kinetics or body composition were found. Angiotensin II-stimulated forearm vasoconstriction is increased in viscerally obese normotensive men. /Palmitate/ |
References | |
Additional Infomation |
A common saturated fatty acid found in fats and waxes including olive oil, palm oil, and body lipids.
Mechanism of Action Vascular dysfunction is a major complication of metabolic disorders such as diabetes and obesity. The current studies were undertaken to determine whether inflammatory responses are activated in the vasculature of mice with diet-induced obesity, and if so, whether Toll-Like Receptor-4 (TLR4), a key mediator of innate immunity, contributes to these responses. Mice lacking TLR4 (TLR4(-/-)) and wild-type (WT) controls were fed either a low fat (LF) control diet or a diet high in saturated fat (HF) for 8 weeks. In response to HF feeding, both genotypes displayed similar increases of body weight, body fat content, and serum insulin and free fatty acid (FFA) levels compared with mice on a LF diet. In lysates of thoracic aorta from WT mice maintained on a HF diet, markers of vascular inflammation both upstream (IKK-beta activity) and downstream of the transcriptional regulator, NF-kappa-B (ICAM protein and IL-6 mRNA expression), were increased and this effect was associated with cellular insulin resistance and impaired insulin stimulation of endothelial nitric oxide synthase (eNOS). In contrast, vascular inflammation and impaired insulin responsiveness were not evident in aortic samples taken from TLR4(-/-) mice fed the same HF diet, despite comparable increases of body fat mass. Incubation of either aortic explants from WT mice or cultured human microvascular endothelial cells with the saturated FFA, palmitate (100 mol/L), similarly activated IKK-beta, inhibited insulin signal transduction and blocked insulin-stimulated NO production. Each of these effects was subsequently shown to be dependent on both TLR4 and NF-kappa-B activation. These findings identify the TLR4 signaling pathway as a key mediator of the deleterious effects of palmitate on endothelial NO signaling, and are the first to document a key role for TLR4 in the mechanism whereby diet-induced obesity induces vascular inflammation and insulin resistance. /Palmitate/ Insulin stimulates its own secretion and synthesis by pancreatic beta-cells. Although the exact molecular mechanism involved is unknown, changes in beta-cell insulin signalling have been recognized as a potential link between insulin resistance and its impaired release, as observed in non-insulin-dependent diabetes. However, insulin resistance is also associated with elevated plasma levels of free fatty acids (FFA) that are well known modulators of insulin secretion by pancreatic islets. This information led us to investigate the effect of FFA on insulin receptor signalling in pancreatic islets. Exposure of pancreatic islets to palmitate caused up-regulation of several insulin-induced activities including tyrosine phosphorylation of insulin receptor and pp185. This is the first evidence that short exposure of these cells to 100 microM palmitate activates the early steps of insulin receptor signalling. 2-Bromopalmitate, a carnitine palmitoyl-CoA transferase-1 inhibitor, did not affect the effect of the fatty acid. Cerulenin, an acylation inhibitor, abolished the palmitate effect on protein levels and phosphorylation of insulin receptor. This result supports the proposition that protein acylation may be an important mechanism by which palmitate exerts its modulating effect on the intracellular insulin signalling pathway in rat pancreatic islets. Accumulation of long-chain fatty acids in the heart has been proposed to play a role in the development of heart failure and diabetic cardiomyopathy. Several animal models with increased cardiomyocyte lipid accumulation suggest a link between the accumulation of lipid, cardiomyocyte cell death and the development of cardiomyopathy. In this review, we discuss the mechanism through which fatty acid accumulation may contribute to the development or progression of heart failure by initiation of apoptotic cell death. Long-chain saturated fatty acids induce apoptosis through a mechanism involving the generation of reactive intermediates. Reactive intermediate production occurs in concert with de novo ceramide synthesis, but ceramide production is not required for cell death. Cardiomyocyte dysfunction and death from reactive intermediates generated by long-chain saturated fatty acids may contribute to the pathogenesis of human heart disease. /Long-chain Fatty Acids/ |
Molecular Formula |
C16H31NAO2
|
---|---|
Molecular Weight |
278.41
|
Exact Mass |
278.222
|
CAS # |
408-35-5
|
Related CAS # |
Palmitic acid;57-10-3;Palmitic acid-13C16 sodium;2483736-17-8;Palmitic acid-d31 sodium;467235-83-2;Palmitic acid-d31;39756-30-4;Palmitic acid-1-13C;57677-53-9;Palmitic acid-d2;62689-96-7;Palmitic acid-d3;75736-53-7;Palmitic acid-13C16;56599-85-0;Palmitic acid-d4;75736-49-1;Palmitic acid-13C;287100-87-2;Palmitic acid-13C sodium;201612-54-6;Palmitic acid-d3 sodium;347841-37-6;Palmitic acid-1,2,3,4-13C4;287100-89-4;Palmitic acid-15,15,16,16,16-d5;285979-77-3;Palmitic acid-13C2;86683-25-2;Palmitic acid-d2-1;62690-28-2;Palmitic acid-9,10-d2;78387-70-9
|
PubChem CID |
2735111
|
Appearance |
White to off-white solid powder
|
Boiling Point |
340.6ºC at 760mmHg
|
Melting Point |
283-290 °C(lit.)
|
Flash Point |
154.1ºC
|
LogP |
4.217
|
Hydrogen Bond Donor Count |
0
|
Hydrogen Bond Acceptor Count |
2
|
Rotatable Bond Count |
14
|
Heavy Atom Count |
19
|
Complexity |
184
|
Defined Atom Stereocenter Count |
0
|
InChi Key |
GGXKEBACDBNFAF-UHFFFAOYSA-M
|
InChi Code |
InChI=1S/C16H32O2.Na/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16(17)18;/h2-15H2,1H3,(H,17,18);/q;+1/p-1
|
Chemical Name |
sodium;hexadecanoate
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 11.11 mg/mL (39.91 mM)
H2O: < 0.1 mg/mL |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.11 mg/mL (3.99 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 11.1 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.5918 mL | 17.9591 mL | 35.9183 mL | |
5 mM | 0.7184 mL | 3.5918 mL | 7.1837 mL | |
10 mM | 0.3592 mL | 1.7959 mL | 3.5918 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.